Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated